The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000623392p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
26/04/2026
Date registered
Help: Date registered
21/05/2026
Date last updated
Help: Date last updated
21/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
EnteraL rathEr thAn iNtravenous Electrolyte Replacement in critically ill patients (LEANER)
Scientific title
EnteraL rathEr thAn iNtravenous Electrolyte Replacement in critically ill patients (LEANER): A prospective, hybrid type I effectiveness implementation, stepped-wedge, cluster-randomised, non-inferiority, registry-based pragmatic trial to evaluate the effectiveness and acceptability of enteral rather than intravenous electrolyte replacement.
Additional trial identifiers [1] 317118 0
Nil known
Universal Trial Number (UTN)
U1111-1339-8380
Trial acronym
LEANER
Related trial records

Health condition
Health condition(s) studied:
Electrolyte deficiency 341774 0
Critical illness 341775 0
Condition category
Condition code
Metabolic and Endocrine 337751 337751 0 0
Metabolic disorders
Public Health 337752 337752 0 0
Health service research
Diet and Nutrition 337977 337977 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study will compare two routes of electrolyte replacement focusing on magensium and phosphate electrolytes. Critically ill patients in the ICU with either hypomagnesemia and/or hypophosphatemia will be adminstered electrolyte replacement either via the gut (enteral route) or via intravenous infusion (IV route). Both routes are current standard care.

All doses will be prescribed per treating ICU clinician and will typically be prescribed as per standard ICU policy or guidelines. The decision on exact dose amount and frequency will be assessed for each individual patient, taking into consideration several factors such as the cause and severity of hypomagnesemia and/or hypophosphatemia. This trial is designed to be a pragmatic trial that reflects current standard prescribing and administration practice.

Enteral dose magnesium:
Magnesium aspartate dihydrate, 500 mg (equivalent to 37.4 mg or 1.55 mmol elemental magneium), 1-3 tablets TWO to THREE times daily, dissolved in water (typically 100ml) and administered via gastric tube.
Enteral dose phosphate:
Monophasic sodium phosphate, 500mg effervescent tablet (equivalent to 1.936 g monobasic sodium or 16 mmol) phosphate ions), 1 to 2 tablets BD - TDS dissolved in water (typically 100ml) and administered via gastric tube.

The patient's medication chart in the medical record will be checked for administration of dose and route. ICU pharmacists will participate in weekly adherence checks during the intervention period. The pharmacists typically review patient medication charts daily and attend daily ICU ward rounds with medical and nursing staff. Hence are best placed to perform adherence checks. The weekly checks will be performed on one day, each week as a point of prevalence check. They will review all patients in the ICU on the day of the check for any electrolyte administered in previous 24hrs. Where the route was given against the cluster allocation (eg. IV instead of enteral) these will be recorded as protocol deviations. The pharmacists will also be able to provide ongoing education and reminders to staff in the ICU of the need to comply to cluster allocation of route wherever clincally appropriate to do so.

A time and motion study will be embedded as a process evaluation in the trial. The aim of the trial and motion study will be to observe processes involved in prescribing and administering electrolyte replacement. An independent observer (research coordinator) will time medical staff on how long it takes and how many steps are performed (ie. click of the computer mouse) to navigate an electronic medication chart when prescribing an enteral and an IV dose of both magnesium and phosphate. In addition, nursing staff will be observed for preparation and administration of enteral and IV doses of magnesium and phosphate. Overall time taken will be recorded and a count of the number of individual steps to perform the administration task. A record will be documented of the type and number of consumables used during the administration task (ie. syringes, vials, IV fluid bags etc.). This information will be used in cost-effective and life cycle analyses.
Intervention code [1] 333878 0
Treatment: Drugs
Description of the comparator or control
Intravenous route magnesium and phosphate replacement - to be prescribed and administered as per treating ICU clinical team to treat hypomagnesemia and/or hypophosphatemia.
Intravenous Magnesium:
Magnesium Sulfate, 465 g/5 mL (49.3%) magnesium sulfate heptahydrate (or 493 mg/mL) (10 mmol of magnesium ions and 10 mmol of sulfate ions). 10-20 mmol of magnesium sulfate in 100 mL of compatible intravenous fluid infused at a rate no faster than 20 mmol/hour.
Magnesium Chloride, 480mg in 5 mL ampoules (5 mmol of magnesium ions and 10 mmol of chloride ions). Dilute 10mmol (10mL) or 20 mmol (20mL) of magnesium chloride in 250 mL of sodium chloride 0.9%, administer over 90 minutes.
Intravenous Phosphate:
Sodium dihydrogen phosphate, 15.6% injection (1.56 g) in 10 mL (10mmol phosphate, 10 mmol sodium). 10-20mmol diluted in 100-250ml of either sodium chloride 0.9% or glucose 5% and administered over 1-4hrs.
Potassium dihydrogen phosphate, 13.6% injection (1.36 g) in 10 mL (10 mmol potassium, 10 mmol phosphate). 10-20mmol diluted in 100-250ml of either sodium chloride 0.9% or glucose 5% and administered over 1-4hrs.

Control group
Active

Outcomes
Primary outcome [1] 345202 0
The trial design is a hybrid type I implmentation-effectiveness trial. It has co-primary major outcomes for clinical effectiveness. Each co-primary outcome will be assessed independently. Implementation effectiveness: 1. Serum magnesium concentration levels
Timepoint [1] 345202 0
Baseline (pre-dose) and 24 hrs post administration of first electrolyte replacement episode
Primary outcome [2] 345203 0
Co-primary effectiveness outcome: 2. Serum phosphate concentration levels
Timepoint [2] 345203 0
Baseline (pre-dose) and 24 hrs post administration of first electrolyte replacement episode
Primary outcome [3] 345313 0
Implementation outcome: 1. Stakeholder acceptability
Timepoint [3] 345313 0
Baseline and end of study
Secondary outcome [1] 460946 0
Serum magnesium concentration levels censored at day 7
Timepoint [1] 460946 0
48 hrs (day 2), 72 hrs (day 3), 96 hrs (day 4), 96 hrs (day 5), 120 hrs (day 6), 144 hrs (day 7) post initial administration episode.
Secondary outcome [2] 460947 0
Serum phosphate concentration levels censored at day 7
Timepoint [2] 460947 0
48 hrs (day 2), 72 hrs (day 3), 96 hrs (day 4), 96 hrs (day 5), 120 hrs (day 6), 144 hrs (day 7) post initial administration episode.
Secondary outcome [3] 460948 0
New onset atrial fibrillation (NOAF)
Timepoint [3] 460948 0
Incidence occuring at any time during ICU admission until discharge from ICU
Secondary outcome [4] 460949 0
Laboratory-confirmed blood stream infections (Central-line associated bloodstream infection (CLABSI) and/or peripheral-line bloodstream associated infection (PLABSI)). Both CLABSI and PLABSI will be assessed as one composite outcome. Isolation of one or more recognized bacterial or fungal pathogens from one or more blood cultures (e.g., Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Proteus, Salmonella species, Candida albicans). Note: Where mixed isolates are obtained with one being an accepted pathogen, the potential contaminant organism is to be disregarded.
Timepoint [4] 460949 0
Occuring at any timepoint on the date of or after administration of IV electrolyte replacment until ICU discharge
Secondary outcome [5] 460951 0
Duration of admission (ICU and hospital) measured in days.
Timepoint [5] 460951 0
Date of discharge from ICU and hospital.
Secondary outcome [6] 460952 0
In-hospital mortality
Timepoint [6] 460952 0
Status as deceased if recorded during hospital admission. Outcome assesessed upon death.
Secondary outcome [7] 460953 0
Duration of invasive mechanical ventilation (hours)
Timepoint [7] 460953 0
Total number of invasive mechanical ventilation hours during ICU admission - assessed at ICU discharge (end of ICU admission)
Secondary outcome [8] 460954 0
Severe diarrhoea
Timepoint [8] 460954 0
Occuring at any time in first 7 days post initial electrolyte replacement
Secondary outcome [9] 460956 0
Cost effectiveness (healthcare cost for enteral and parenteral (IV) magnesium and phosphate use per patient.
Timepoint [9] 460956 0
Assessed after all participants have completed electrolyte replacement. Pharmacy procurement will be calculated as cost of vials/tablets at start of trial.
Secondary outcome [10] 460957 0
Environmental impact, as reported in grams carbon dioxide equivalents (gCO2e). This will be informed by an embedded time-and-motion study which counts number of consumables used in administration process for four administration episodes for enteral electrolyte administration at each participating ICU site. Consumables counted include medication tablets and all packaging, enteral syringes, enteral feeding sets, bottled water (if used). This data, along with end-of-life impacts (medical waste and landfill), will be modelled in SimaPro LCA software, using international and Australian background databases (ecoinvent and AusLCI). Reporting will be provided in kg CO2 equivalents (kg CO2e), showing the consequential carbon impacts of enteral route of administration.
Timepoint [10] 460957 0
Five administration episodes of enteral administration for magnesium and phosphate electrolytes will be observed as a time-and-motion study embedded throughout the study recruitment duration (across 8-months).
Secondary outcome [11] 461264 0
Environmental impact o f waste (environmental impact and amount of waste used in delivery of parenteral (IV) route electrolyte administration). This will be informed by an embedded time-and-motion study which counts number of consumables used in administration process for four administration episodes of parenteral electrolyte administration at each participating ICU site. Consumables counted include glass vials and all packaging, PVC IV fluid bags, plastic IV administration sets and burettes, IV syringes, alcohol swabs, aspiration needles. This data, along with end-of-life impacts (medical waste and landfill), will be modelled in SimaPro LCA software, using international and Australian background databases (ecoinvent and AusLCI). Reporting will be provided in kg CO2 equivalents (kg CO2e), showing the consequential carbon impacts of parenteral (IV) route of administration.
Timepoint [11] 461264 0
Five administration episodes of parenteral (IV) administration for magnesium and phosphate electrolytes will be observed as a time-and-motion study embedded throughout the study recruitment duration (across 8-months).

Eligibility
Key inclusion criteria
All adult patients admitted to the ICU where the clinician wishes to prescribe electrolyte magnesium or phosphate replacement
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patients will be excluded because of:
1. Age less then 18 years
2. Severe life-threatening arrythmia requiring specific electrolyte treatment
3. Either enteral or parenteral (IV) replacement is not possible or not required: No enteric feeding tube, intolerance of enteral feeding with aspiration of gastric contents (gastric residual volume) exceeding 500ml, clinician order to avoid enteral medication administration (eg. post gastrointestinal surgery), no intravenous access, able to swallow whole medication orally.
4. Routine use of enteral magnesium or phosphate supplements prior to ICU admission.
5. Pregnancy


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
This is a prospective, stepped-wedge, cluster-randomised trial. All ICUs will begin treatment allocation together as intravenous electrolyte replacement. This is considered standard care. There will be two ICUs per cluster, with 7 clusters in total. Allocation of which cluster each ICU is allocated will be controlled by biostatistician team. Allocation of random selection of which clusters will move to intervention (enteral route electrolyte replacement) will be controlled by the biostatistician team via the allocation schedule. The biostatistician team are located at central administration site.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Stepped-wedge, cluster-randomised trial.
14 ICUs will be randomly clustered into seven groups of two ICUs (a single cluster). Thus forming seven clusters in total. All clusters will commence at baseline with intravenous route (step one = time period one). This time period is one month duration. Each cluster will then be randomised to transition to enteral route administration in a staggered (step-wise) fashion across seven timepoints (7 steps = 7 time periods). For example, at step 2, one cluster (two ICUs) will transition to enteral route. At step 3, another cluster will transition to enteral route and so forth until all 7 clusters have transitioned to enteral route at step 8 (timepoint 8). Each step (timepoint) will be one month duration. Hence, total time period of trial will be 8 months.
Clustering and timing of transition will be assigned independently by biostatistical team at random using statistical software package.
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis
Clinical effectiveness outcomes (quantitative data):
Primary and secondary analyses will be undertaken using linear (continuous outcomes) or logistic (binary outcomes) mixed-effects models, with intervention and time period as fixed effects, and cluster as a random effect. For continuous outcomes, we will adjust for the outcome at baseline. We will present one-tailed, 97.5% confidence intervals, and assess inferiority/non-inferiority/uncertainty of inferiority based on the 0.1 mmol/L margin. A one-sided alpha of 0.0125 was chosen to penalize for the co-primary outcomes. We will use an intra-cluster correlation of 0.01 to account for differences between clusters. Analysis will be intention to treat. There shoud be minimal missing data, but we will investigate the extent and pattern of missing data.

Implementation outcomes (qualitative data):
Analysis will be based on the 5-stage iterative process: (1) development of coding schedule; (2) coding data; (3) description of main categories; (4) linking categories into major themes (5) development of explanations for relations between themes. A thematic analysis approach to identify factors affecting acceptability from staff surveys and focus group discussions will be utilized; that is, the survey and interview questions will be informed by the Theoretical Framework of Acceptability (TFA) and while we may potentially map the themes according to this framework, we allow new themes to emerge from the data. Deductive coding will be used to organise the data in line with each of the TFA domains. Inductive coding will generate themes that align with the most prominent TFA domains identified. NVivo software (version 12 for Windows, QSR International, Burlington, MA, USA, https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/support-services/nvivo-downloads) will be used to organise the data.

All statistical analysis will be overseen and verified by A/Prof Emily Karahalios, Biostatistician with the Methods and Implementation Support for Clinical Health (MISCH) Research hub at the University of Melbourne. Analyses will be conducted using Stata (StataCorp, 2019, Stata Stistical Software: Release 16, College Station, TX: StataCorp LLC).

Health economic analysis will be conducted by Dr An Tran-Duy, Health Economist at MISCH hub. In health economic analysis, the endpoints that represent treatment effectiveness will be cases with severe hypomagnesemia and hypophosphatemia, blood stream infections, number of days in ICU and deaths. The type of health economic analysis will be decided based on the difference in the effectiveness between the two treatment arms. If our study shows that our primary outcome is non-inferior between enteral route and parenteral route, a cost minimisation analysis will be confucted. Otherwise, a cost-effectiveness analysis will be performed.

Total cost associated with each intervention will be calculated based on cost of the medication, cost of delivery of the treatment, cost of adverse events associated with the intervention, and hospital cost. In the cost-minimization analysis, the total costs, adjusted for the difference in the patient baseline characteristics, will be compared between the two interventions. In the cost-effectiveness analysis, incremental cost per case of severe hypomagnesemia and hypophosphatemia, per blood stream infection prevented, per necessity to insert fecal contanment device for severe diarrhoea, per day in ICU reduced and per death prevented in patients receiving enteral magnesium and phosphate replacement compared to parenteral magnesium and phosphate replacement will be calculated. Probabilistic sensitivity analysis will be conducted using the bootstrap method.

The embedded time-and-motion study will provide total time recorded for nursing staff to prepare and administer electrolyte replacement. The total time taken will be measured and converted to labour cost using a corresponding mean hourly wage rate. Total labour cost will be summarised, assuming a nurse-to-patient ratio of 1:1. Other direct costs such as medication and consumable supplies will be captured separately during cost-minimisation analysis.

Dr Scott McAlister, Research Fellow in the Centre for Health Policy at the Melbourne School of Population and Global Health, University of Melbourne, will conduct measurement of environmental impacts of magnesium and phosphate replacement.

To quantify carbon impacts of magnesium and phosphate replacement, a time-and-motion study will collect data on 4 administration episodes of magnesium and phosphate replacment for each of enteral and parenteral administrations across each of the 14 participating ICU sites. Hence, this will provide total 224 This data will be analysed using consequential life cycle assessment (LCA).
We will collect all the consumables associated with providing intravenous magnesium and enteral magnesium replacement. This will include glass vials of magnesium sulfate, all packaging, syringes used to aspirate magnesium solution from vials, blunt aspiration needles, and fluid bags used to dilute magnesium for infusion. This data, along with end-of-life impacts (medical waste and landfill), will be modelled in SimaPro? LCA software, using international and Australian background databases (ecoinvent and AusLCI). Reporting will be provided in kg CO2 equivalents (kg CO2e), showing the consequential carbon impacts of each route of administration.


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC

Funding & Sponsors
Funding source category [1] 321697 0
Charities/Societies/Foundations
Name [1] 321697 0
Intensive Care Foundation
Country [1] 321697 0
Australia
Funding source category [2] 321698 0
Hospital
Name [2] 321698 0
Plenary Health Innovation Grant, Western Health Foundation, Western Health
Country [2] 321698 0
Australia
Funding source category [3] 321699 0
Government body
Name [3] 321699 0
Australian Academy of Science Douglas and Lola Douglas Scholarship in Medical Science
Country [3] 321699 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324531 0
None
Name [1] 324531 0
Address [1] 324531 0
Country [1] 324531 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320235 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 320235 0
Ethics committee country [1] 320235 0
Australia
Date submitted for ethics approval [1] 320235 0
29/05/2026
Approval date [1] 320235 0
Ethics approval number [1] 320235 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149846 0
Prof Adam Deane
Address 149846 0
Intensive Care Unit, Level 5, Building B, The Royal Melbourne Hospital, 300 Grattan St, Parkville, VIC, 3050
Country 149846 0
Australia
Phone 149846 0
+61 3 9342 9254
Fax 149846 0
Email 149846 0
Contact person for public queries
Name 149847 0
Ms Samantha Bates
Address 149847 0
Intensive Care Unit, Level 6, Footscray Hospital, 89 Ballarat Rd, Footscray, VIC, 3011
Country 149847 0
Australia
Phone 149847 0
+61 421 684 985
Fax 149847 0
Email 149847 0
Contact person for scientific queries
Name 149848 0
Ms Samantha Bates
Address 149848 0
Intensive Care Unit, Level 6, Footscray Hospital, 89 Ballarat Rd, Footscray, VIC, 3011
Country 149848 0
Australia
Phone 149848 0
+61 421 684 985
Fax 149848 0
Email 149848 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Systematic reviews and meta-analyses
• Studies testing whether findings can be repeated or confirmed
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Approval from Australian and New Zealand Intensive Care Society Clinical Trials Group



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.